These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 808456)

  • 1. Pathogenesis and management of iron overload in thalassemia.
    Hershko C
    Haematologica; 1975 Jun; 60(2):241-8. PubMed ID: 808456
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P
    Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract]   [Full Text] [Related]  

  • 3. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
    Cesana M; Mandelli C; Tiribelli C; Bianchi PA; Conte D
    Am J Gastroenterol; 1989 Feb; 84(2):150-2. PubMed ID: 2916524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron overload: pathogenesis and treatment with chelating agents.
    Huebers H
    Blut; 1983 Aug; 47(2):61-7. PubMed ID: 6871476
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of iron overload.
    Cohen A; Witzleben C; Schwartz E
    Semin Liver Dis; 1984 Aug; 4(3):228-38. PubMed ID: 6091277
    [No Abstract]   [Full Text] [Related]  

  • 7. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

  • 9. Recognition and treatment of iron overload.
    Brown EB
    Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of primary siderochromatosis and siderosis: experimental and clinical study].
    Bianco G; Gallo E; Ramello A; Ricco G; Matone S
    Minerva Med; 1969 Dec; 60(97):4881-90. PubMed ID: 5357552
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical usefulness of iron chelating agents.
    Waxman HS; Brown EB
    Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
    Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
    [No Abstract]   [Full Text] [Related]  

  • 13. Iron balance and the management of iron overload in beta-thalassemia intermedia.
    Pippard MJ; Weatherall DJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):29-33. PubMed ID: 3390555
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
    Lévy G; Bachelot C; Joannard A; Bost M
    Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 17. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
    Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF
    Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurement of iron status.
    Pippard MJ
    Prog Clin Biol Res; 1989; 309():85-92. PubMed ID: 2675108
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thalassemia minor with iron overload: genetic and clinical study of a family].
    Queipo de Llano MP; Yebra M; Moreno M; Lacoma F; Gea JC; Berrocal E
    Med Clin (Barc); 1991 Nov; 97(17):660-2. PubMed ID: 1762461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.